



State of California—Health and Human Services Agency
California Department of Public Health



KAREN L. SMITH, MD, MPH
Director & State Health Officer

EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2016-08

Date: May 3, 2016

TO: LOCAL ADAP COORDINATORS
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF EMTRICITABINE/TENOFOVIR ALAFENAMIDE
(DESCOVY®) TO THE ADAP FORMULARY

Effective May 3, 2016, emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) (Descovy®), has been added to the ADAP formulary. F/TAF is a new combination antiretroviral (ARV) that was approved by the federal Food and Drug Administration (FDA) on April 4, 2016. This new ARV is indicated in combination with other ARV drugs for the treatment of HIV-1 infected patients.

With the addition of this ARV, the ADAP formulary consists of 199 drugs, including those necessary to treat HIV in accordance with the federal treatment guidelines for HIV/AIDS and associated opportunistic infections.

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact me at (916) 449-5942 or Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Niki Dhillon, Chief
ADAP Branch
Office of AIDS